| Identification | Back Directory | [Name]
H-GLU-TRP-OH | [CAS]
38101-59-6 | [Synonyms]
EW
Timogen
GLU-TRP
Z-Glu-Trp
Ccris 8677
NSC 334073
Oglufanide
Glu-Trp HAc
H-GLU-TRP-OH
ALPHA-L-GLU-L-TRP
Glutamyltryptophan
Glutamyl tryptophan
Thymogen(Oglufanide)
L-Glutamyl-L-tryptophan
alpha-glutamyltryptophan
L-Tryptophan, L-α-glutamyl-
ThyMogen, Oglufanide, IM862
L-Tryptophan, L-a-glutaMyl-
L-alpha-Glutamyl-L-tryptophan
L-Tryptophan, N-L-alpha-glutamyl-
H-GLU-TRP-OH;L-GLUTAMYL-L-TRYPTOPHAN;THYMOGEN;IM862
4-amino-5-[[1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoicacid | [Molecular Formula]
C16H19N3O5 | [MDL Number]
MFCD00037953 | [MOL File]
38101-59-6.mol | [Molecular Weight]
333.34 |
| Chemical Properties | Back Directory | [Melting point ]
121-122℃ | [Boiling point ]
738.9±60.0 °C(Predicted) | [density ]
1.428 | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
DMSO : 15.5 mg/mL (46.50 mM) | [form ]
Solid | [pka]
3.09±0.10(Predicted) | [color ]
White to off-white | [InChI]
InChI=1/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/s3 | [InChIKey]
LLEUXCDZPQOJMY-PZILLZCRNA-N | [SMILES]
C(C1=CNC2=CC=CC=C12)[C@@H](C(=O)O)NC(=O)[C@@H](N)CCC(=O)O |&1:10,17,r| |
| Hazard Information | Back Directory | [Uses]
Treatment of Kaposi’s sarcoma and solid tumor cancers (angiogenesis inhibitor); immunomodulator. | [Definition]
ChEBI: A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. | [in vivo]
Oglufanide (L-glu-L-trp) (1-100 mg/kg/day; s.c.; 10 days) has antitumor activity in immunocompetent and immunodeficient mice[4]. | Animal Model: | C57BL/6 immune competent mice, Lewis lung carcinoma (LLC) xenograft; Balb/C athymic mice, M21 human melanoma xenograft[4] | | Dosage: | 1, 10, 50 and 100 mg/kg/day | | Administration: | Subcutaneous injection, 10 days | | Result: | Resulted in a dose-dependent inhibition of LLC tumor growth in syngeneic immune competent mice and showed a dose-dependent decrease in tumor volumes of xenografts in Balb/C athymic mice implanted with M21 human melanoma cells. |
| [IC 50]
VEGFR; HCV; Human Endogenous Metabolite |
|
|